MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hatse, S.
Right arrow Articles by Schols, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hatse, S.
Right arrow Articles by Schols, D.

Vol. 60, Issue 1, 164-173, July 2001

Mutation of Asp171 and Asp262 of the Chemokine Receptor CXCR4 Impairs Its Coreceptor Function for Human Immunodeficiency Virus-1 Entry and Abrogates the Antagonistic Activity of AMD3100

Sigrid Hatse, Katrien Princen, Lars-Ole Gerlach, Gary Bridger, Geoffrey Henson, Erik De Clercq, Thue W. Schwartz, and Dominique Schols

Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium (S.H., K.P., E.D.C., D.S.); The Panum Institute, Copenhagen, Denmark (L-O.G., T.W.S.); and AnorMed, Langley, British Columbia, Canada (G.B., G.H.)

The bicyclam AMD3100 is a highly potent and selective CXCR4 antagonist with strong antiviral activity against human immunodeficiency virus (HIV)-1 and HIV-2, which use CXCR4 as coreceptor for host cell entry. Here, we investigated the interaction of AMD3100 with CXCR4 at the molecular level by mutational analysis. We established a set of stably transfected U87.CD4 cell lines expressing different mutant forms of CXCR4 (i.e., CXCR4[WT], CXCR4[D171N], CXCR4[D262N], CXCR4[D171N,D262N], and CXCR4[H281A]), to compare the activity of the compound against mutated versus wild-type CXCR4. We found that the antagonistic action of AMD3100 against CXCR4---as assessed by the inhibitory effects of the compound on stromal cell-derived factor (SDF-1) binding to its receptor and on SDF-1-induced intracellular calcium signaling, and by displacement of the CXCR4-specific antibody, clone 12G5---was greatly reduced by substitution of Asp171 and/or Asp262 by neutral asparagine residue(s). Both aspartates, but most particularly Asp262, also proved essential for the anti-HIV-1 activity of AMD3100 against the viruses NL4.3, IIIB, and HE. In contrast, substitution of His281 by a neutral alanine potentiated the antagonistic and antiviral effects of the compound in the different assay systems. Importantly, compared with the wild-type receptor, CXCR4[D262N] was much less effective, whereas CXCR4[D171N,D262N] completely failed as a coreceptor for infection by HIV-1 NL4.3. Thus, the negatively charged aspartate residues at positions 171 and 262, located in transmembrane domains 4 and 6 of the 7-transmembrane receptor, respectively, may represent crucial sites for electrostatic interaction of the positive charges of the bicyclams, as well as for the highly basic V3 loop of the gp120 envelope protein of certain HIV-1 strains.

Copyright © 2001 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 Mol. Pharmacol.Home page
R. S. Y. Wong, V. Bodart, M. Metz, J. Labrecque, G. Bridger, and S. P. Fricker
Comparison of the Potential Multiple Binding Modes of Bicyclam, Monocylam, and Noncyclam Small-Molecule CXC Chemokine Receptor 4 Inhibitors
Mol. Pharmacol., December 1, 2008; 74(6): 1485 - 1495.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
S. Fransen, G. Bridger, J. M. Whitcomb, J. Toma, E. Stawiski, N. Parkin, C. J. Petropoulos, and W. Huang
Suppression of Dualtropic Human Immunodeficiency Virus Type 1 by the CXCR4 Antagonist AMD3100 Is Associated with Efficiency of CXCR4 Use and Baseline Virus Composition
Antimicrob. Agents Chemother., July 1, 2008; 52(7): 2608 - 2615.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
G. Lin, A. Bertolotti-Ciarlet, B. Haggarty, J. Romano, K. M. Nolan, G. J. Leslie, A. P.-O. Jordan, C.-c. Huang, P. D. Kwong, R. W. Doms, et al.
Replication-Competent Variants of Human Immunodeficiency Virus Type 2 Lacking the V3 Loop Exhibit Resistance to Chemokine Receptor Antagonists
J. Virol., September 15, 2007; 81(18): 9956 - 9966.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. M. Rosenkilde, L.-O. Gerlach, S. Hatse, R. T. Skerlj, D. Schols, G. J. Bridger, and T. W. Schwartz
Molecular Mechanism of Action of Monocyclam Versus Bicyclam Non-peptide Antagonists in the CXCR4 Chemokine Receptor
J. Biol. Chem., September 14, 2007; 282(37): 27354 - 27365.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
C. Xu, J. Sui, H. Tao, Q. Zhu, and W. A. Marasco
Human Anti-CXCR4 Antibodies Undergo VH Replacement, Exhibit Functional V-Region Sulfation, and Define CXCR4 Antigenic Heterogeneity
J. Immunol., August 15, 2007; 179(4): 2408 - 2418.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
S. Hatse, D. Huskens, K. Princen, K. Vermeire, G. J. Bridger, E. De Clercq, M. M. Rosenkilde, T. W. Schwartz, and D. Schols
Modest Human Immunodeficiency Virus Coreceptor Function of CXCR3 Is Strongly Enhanced by Mimicking the CXCR4 Ligand Binding Pocket in the CXCR3 Receptor
J. Virol., April 1, 2007; 81(7): 3632 - 3639.
[Abstract] [Full Text] [PDF]

Home page
 J. Gen. Virol.Home page
A. Lauren, D. Vodros, R. Thorstensson, and E. M. Fenyo
Comparative studies on mucosal and intravenous transmission of simian immunodeficiency virus (SIVsm): evolution of coreceptor use varies with pathogenic outcome.
J. Gen. Virol., March 1, 2006; 87(Pt 3): 581 - 594.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
K. Princen, S. Hatse, K. Vermeire, S. Aquaro, E. De Clercq, L.-O. Gerlach, M. Rosenkilde, T. W. Schwartz, R. Skerlj, G. Bridger, et al.
Inhibition of Human Immunodeficiency Virus Replication by a Dual CCR5/CXCR4 Antagonist
J. Virol., December 1, 2004; 78(23): 12996 - 13006.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
J. Balzarini, S. Hatse, K. Vermeire, K. Princen, S. Aquaro, C.-F. Perno, E. De Clercq, H. Egberink, G. Vanden Mooter, W. Peumans, et al.
Mannose-Specific Plant Lectins from the Amaryllidaceae Family Qualify as Efficient Microbicides for Prevention of Human Immunodeficiency Virus Infection
Antimicrob. Agents Chemother., October 1, 2004; 48(10): 3858 - 3870.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
M. Gouwy, S. Struyf, J. Catusse, P. Proost, and J. Van Damme
Synergy between proinflammatory ligands of G protein-coupled receptors in neutrophil activation and migration
J. Leukoc. Biol., July 1, 2004; 76(1): 185 - 194.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
A. Sachpatzidis, B. K. Benton, J. P. Manfredi, H. Wang, A. Hamilton, H. G. Dohlman, and E. Lolis
Identification of Allosteric Peptide Agonists of CXCR4
J. Biol. Chem., January 3, 2003; 278(2): 896 - 907.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
E. G. Cormier and T. Dragic
The Crown and Stem of the V3 Loop Play Distinct Roles in Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Interactions with the CCR5 Coreceptor
J. Virol., July 29, 2002; 76(17): 8953 - 8957.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2001 by the American Society for Pharmacology and Experimental Therapeutics